

# Adrenoleukodystrophy Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035

<https://marketpublishers.com/r/AA311116E2DBEN.html>

Date: June 2025

Pages: 0

Price: US\$ 4,900.00 (Single User License)

ID: AA311116E2DBEN

## Abstracts

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at [order@marketpublishers.com](mailto:order@marketpublishers.com) with your request.

This report will be delivered in 7-10 working days. Industry Overview

The global adrenoleukodystrophy market is currently in the growth stage of its lifecycle. Having transitioned from the introduction phase, where treatment options were limited and awareness was low, the market is now experiencing increased interest due to advances in gene therapy-based treatments and innovative drug therapies. Rising diagnostic capabilities, such as newborn screening programs, have contributed to earlier detection, driving demand for therapeutic interventions. Furthermore, the emergence of orphan drug programs and government support for rare diseases has spurred market growth. However, the market still faces challenges, including high treatment costs and a relatively small patient base, which may limit rapid expansion. Overall, while the market is growing, it remains highly specialized and will continue to evolve the rare disease landscape with ongoing research and development.

## Impact

Increasing demand for adrenoleukodystrophy therapies is anticipated to support the growth of the global adrenoleukodystrophy market during the forecast period 2025-2035.

The global adrenoleukodystrophy market is expected to grow at a significant rate due to developments in targeted therapies, rising awareness and diagnosis, and a growing clinical pipeline, alongside advancements in healthcare infrastructure and access to specialized treatments.

## Recent Developments

**Research Activities:** In December 2024, Minoryx Therapeutics and Neuraxpharm Group announced that leriglitazone met the primary endpoint in the NEXUS trial for paediatric patients with cerebral adrenoleukodystrophy (cALD).

## Demand – Drivers and Limitations

### Drivers:

Increasing Prevalence of Adrenoleukodystrophy

Advancements in Treatment Options

Growing Research and Investment in Rare Diseases

### Limitations:

High Treatment Costs

Limited Awareness in Developing Regions

## How Can This Report Add Value to an Organization?

**Product/Innovation Strategy:** Innovations in the global adrenoleukodystrophy market are centered on advancing treatment options to enhance patient care. Key players in the market, such as Minoryx Therapeutics and NeuraxPharm, have been involved in the development of therapies for adrenoleukodystrophy.

**Competitive Strategy:** Enterprises led by market leaders continually update their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product pipeline and innovation. This benchmarking

provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.

### Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolios, and market penetration.

Some of the prominent names established in this market are:

bluebird bio

Minoryx Therapeutics, S.L.

MedDay Pharmaceuticals

Viking Therapeutics

Neuraxpharm Group

## Contents

Executive Summary

Scope of Study

### **1. GLOBAL ADRENOLEUKODYSTROPHY MARKET OVERVIEW**

#### 1.1 Industry Outlook

1.1.1 Market Overview and Ecosystem

1.1.2 Market Trends

1.1.3 Epidemiological Analysis of Adrenoleukodystrophy

1.1.4 Clinical Trials

1.1.4.1 By Phase

1.1.4.2 By Sponsor Type

1.1.5 Regulatory Landscape / Compliance

#### 1.2 Market Dynamics

1.2.1 Impact Analysis

1.2.2 Market Drivers

1.2.3 Market Restraints

1.2.4 Market Opportunities

### **2. GLOBAL ADRENOLEUKODYSTROPHY MARKET (BY REGION), \$MILLION, 2023-2035**

#### 2.1 North America

2.1.1 Market Dynamics

2.1.2 Market Size and Forecast

2.1.2.1 North America Adrenoleukodystrophy Market (by Country)

2.1.2.1.1 U.S.

#### 2.2 Europe

2.2.1 Market Dynamics

2.2.2 Market Size and Forecast

2.2.2.1 Europe Adrenoleukodystrophy Market (by Country)

2.2.2.1.1 U.K.

2.2.2.1.2 Germany

2.2.2.1.3 France

2.2.2.1.4 Italy

2.2.2.1.5 Spain

#### 2.3 Asia-Pacific

2.3.1 Market Dynamics

2.3.2 Market Size and Forecast

2.3.2.1 Asia-Pacific Adrenoleukodystrophy Market (by Country)

2.3.2.1.1 Japan

### **3. GLOBAL ADRENOLEUKODYSTROPHY MARKET - COMPETITIVE BENCHMARKING AND COMPANY PROFILES**

3.1 Competitive Landscape

3.1.1 Key Strategies and Developments by Company

3.1.1.1 Funding Activities

3.1.1.2 Mergers and Acquisitions

3.1.1.3 Regulatory Approvals

3.1.1.4 Partnerships, Collaborations and Business Expansions

3.1.2 Key Developments Analysis

3.2 Company Profiles

3.2.1 bluebird bio

3.2.1.1 Company Overview

3.2.1.2 Product Portfolio

3.2.1.3 Target Customers/End Users

3.2.1.4 Analyst View

3.2.2 Minoryx Therapeutics, S.L.

3.2.2.1 Company Overview

3.2.2.2 Product Portfolio

3.2.2.3 Target Customers/End Users

3.2.2.4 Analyst View

3.2.3 MedDay Pharmaceuticals

3.2.3.1 Company Overview

3.2.3.2 Product Portfolio

3.2.3.3 Target Customers/End Users

3.2.3.4 Analyst View

3.2.4 Viking Therapeutics

3.2.4.1 Company Overview

3.2.4.2 Product Portfolio

3.2.4.3 Target Customers/End Users

3.2.4.4 Analyst View

3.2.5 Neuraxpharm Group

3.2.5.1 Company Overview

3.2.5.2 Product Portfolio

3.2.5.3 Target Customers/End Users

3.2.5.4 Analyst View

#### **4. RESEARCH METHODOLOGY**

## List Of Figures

### LIST OF FIGURES

Figure: Global Adrenoleukodystrophy Market, Market Overview

Figure: Global Adrenoleukodystrophy Market, Epidemiological Analysis, U.S.

Figure: Global Adrenoleukodystrophy Market Coverage

Figure: Global Adrenoleukodystrophy Market Key Trends, Impact Analysis, 2023-2035

Figure: Global Adrenoleukodystrophy Market, Competitive Landscape, January  
2022-April 2025

## List Of Tables

### LIST OF TABLES

Table: Global Adrenoleukodystrophy Market, Regulatory Scenario

Table: Global Adrenoleukodystrophy Market Dynamics, Impact Analysis

Table: Global Adrenoleukodystrophy Market (by Region), \$Million, 2023-2035



## I would like to order

Product name: Adrenoleukodystrophy Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035

Product link: <https://marketpublishers.com/r/AA311116E2DBEN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AA311116E2DBEN.html>